EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 10
Issue: 7
88-94
Year: 2023

A REVIEW ON RECENT ADVANCES IN BRAIN TARGETED DRUG DELIVERY SYSTEM

Altaf Mulla*[1], Dr. Sameer Shafi[1], Bilal Saberi[1], Saqlain Mustaque[1]

[1]Shivlingeshawar College of Pharmacy, Almala, Tq-Ausa Dist-Latur.

***Corresponding Author: Altaf Mulla**
Shivlingeshawar College of Pharmacy, Almala, Tq-Ausa Dist-Latur.

Article Received on 04/05/2023 **Article Revised on 25/05/2023** **Article Accepted on 15/06/2023**

ABSTRACT

The blood- brain barrier (BBB) has been a great chain for brain medicine delivery. The BBB in healthy brain is a prolixity barrier essential for guarding normal brain function by impeding most composites from coursing from the blood to the brain; only small motes can cross the BBB. Under certain pathological conditions of conditions similar as stroke, diabetes, seizures, multiple sclerosis, Parkinson's complaint and Alzheimer complaint, the BBB is disintegrated. The ideal of this review is to give a broad overview on current strategies for brain medicine delivery and related subjects from the once five times. It's hoped that this review could inspire compendiums to discover possible approaches to deliver medicines into the brain. After an original overview of the BBB structure and function in both healthy and pathological conditions, this review re-visits, according to recent publications, some questions that are controversial, similar as whether nanoparticles by themselves could cross the BBB and whether medicines are specifically transferred to the brain by laboriously targeted nanoparticles. Current non-nanoparticle strategies are also reviewed, similar as delivery of medicines through the passable BBB under pathological conditions and using non-invasive ways to enhance brain medicine uptake. Eventually, one particular area that's frequently neglected in brain medicine delivery is the influence of growing on the BBB, which is captured in this review grounded on the limited studies in the literature.

KEYWORDS: Brain, Drug delivery, Blood-Brain barrier, Nano particles, etc.

INTRODUCTION

The brain is a delicate organ, and nature has veritably efficiently defended it. Medicine delivery into the brain was delicate due to the actuality of blood brain barrier, which only permits some motes to pass through freely. The brain is shielded against potentially poisonous substances by the presence of two main barrier systems the blood brain barrier (BBB) and the blood cerebrospinal fluid barrier (BCSFB). Unfortunately, the same mechanisms that cover it against protrusive chemicals can also frustrate remedial interventions. In once decades, technology has enabled important specialized advancement, including medicine delivery into the brain with high effectiveness and delicacy. The grueling sphere of effective brain delivery has led to a keen scientific pursuit and as a result new styles have been constructed and patented. In the present paper, we epitomize recent important advancements in brain targeted medicine delivery. The central nervous system is defended by BBB and BCF which control the entry of composites into the brain, there by regulating brain homeostasis. barrier restricts access to brain cells of blood – borne composites and facilitates nutrients essential for normal metabolism to reach brain cells. This regulation of the brain homeostasis results in the incapability of some small and large remedial composites to cross the blood – brain barrier BBB). It's estimated that further than 98 of small molecular weight medicines and virtually 100 of large molecular weight medicines (substantially peptides and proteins) developed for CNS pathologies don't readily cross the BBB and discovery of new modalities allowing for effective delivery of medicines and memoir macromolecules to the central nervous system (CNS) is of great need and significance for treatment of neurodegenerative diseases (Alzheimer's complaint, Epilepsy).

Barrier in brain targeted drug delivery: The failure of systemically delivered medicines to effectively treat numerous CNS conditions can be accounted by considering a number of barriers that inhibit medicine delivery to the CNS. There are physical barriers that separate the brain extracellular fluid from the blood.

1. Blood-Brain Barrier
2. Blood-Cerebrospinal Fluid Barrier
3. Blood-Tumor Barrie

Functions of BBB: The blood –The brain barrier acts veritably effectively to cover the brain from numerous common bacterial infections. Therefore, infections of the brain are veritably rare. Infections of the brain that do are frequently veritably serious and delicate to treat. Antibodies are too large to cross the blood- brain barrier and only certain antibiotics are suitable to pass. In some cases, the medicine has to be administered directly into the cerebrospinal fluid. still, medicines delivered directly to the CSF don't effectively access into the brain towel itself, conceivably due to the sinuous nature of the interstitial space in the brain. The blood – brain barrier becomes further passable during inflammation. This allows some antibiotics and phagocytes to move across the BBB. Still, this also allows bacteria and contagions to insinuate the BBB.



Fig 1: Blood Brain Barrier.

1) Blood - Brain Barrier (BBB): The blood – brain barrier (BBB) is a largely picky permeability barrier that separates the circulating blood from the brain extracellular fluid in the central nervous system. The blood brain barrier is formed by capillary endothelial cells, which are connected by tight junctions with an extremely high electrical resistivity of at least0.1 µm. The blood – brain barrier allows the passage of water, some feasts and lipid answerable motes by unresistant prolixity, as well as the picky transport of motes similar as glucose and amino acids that are pivotal for neural function. On the other hand, the blood – brain barrier may help the entry of lipophilic implicit neurotoxins by way of an active transport medium intermediated by Glycoprotein. Astrocytes are necessary to produce the blood – brain barrier. It's estimated that further than 98 of small molecular weight medicines and virtually 100 of large molecular weight medicines substantially peptides and proteins) developed for CNS pathologies don't readily cross the BBB. Endothelial cells circumscribe the prolixity of bitsy objects (e.g. bacteria) and large or hydrophilic motes into the cerebrospinal fluid (CSF), while allowing the prolixity of small hydrophobic motes (e.g. O2, CO2, hormones, etc).

2) Blood - Cerebrospinal Fluid Barrier (BCSFB): The alternate barrier, located at the choroids supersystem, is represented by the blood- cerebrospinal fluid barrier that separates the blood from the cerebrospinal fluid (CSF) which, in turn, runs in the subarachnoid space girding the brain. still, this barrier is not considered as a main route for the uptake of medicines since its face area is5000-fold lower than that of the BBB. CSF can change motes with the interstitial fluid of the brain parenchyma, the passage of blood borne motes into the CSF is also precisely regulated by the BCB. On the external face of the brain the epidermal cells fold over onto themselves to form a double layered structure, which lies between the dura and pia, this is called the arachnoid membrane. Within the double subcaste is the subarachnoid space, which participates in CSF drainage. Passage of substances from the blood through the arachnoid membrane is averted by tight junction. The functions of blood – cerebrospinal fluid barrier is shown in Fig 2.



Fig 2: The blood – cerebrospinal fluid barrier.

3) Blood - Tumor Barrier: Intracranial medicine delivery is indeed more grueling when the target is a CNS excrescence. For illustration, indeed when primary and secondary systemic excrescences respond to chemotherapeutic agents delivered via the cardiovascular system, intracranial metastases frequently continue to grow. In CNS malice where the BBB is significantly compromised, a variety of physiological walls common to all solid excrescences inhibit medicine delivery via the cardiovascular system. likewise, as an excrescence grows large, the vascular face area decreases, leading to a reduction in trans vascular exchange of blood- borne motes. At the same time, intracapillary distance increases, leading to a lesser diffusional demand for medicine delivery to neoplastic cells and due to high interstitial excrescence pressure and the associated peritumoral edema leads to increase in hydrostatic pressure in the normal brain parenchyma conterminous to the excrescence. As a result, the brain may be less passable to medicines than normal brain endothelium. The functions of blood – excrescence barrier is shown in Fig 3.



Fig 3: Comparison between blood-brain-barrier and blood-tumor-barrier.

Mechanism of transfer of drug via blood-brain barrier (BBB)

A. Transmembrane diffusion: Utmost medicine pass through the blood- brain barrier through transmembrane prolixity. Medicine list to the cytomembrane is necessary for this non-saturable process. This medium is favored by small molecular mass & high lipid solubility. A drug that's absorbed by the blood- brain barrier (BBB) membranes must also partition into the doused medium of the brain interstitial fluid to work. A lipid-answerable chemical may thus be trapped by the capillary bed and obstruct its path to the cells behind the blood- brain barrier (BBB). The rate of transport through the blood-brain barrier (BBB) and the number of medicines presented in the brain both influence the chance of administered medicines entering the brain. The largest chemical known to access the blood- brain barrier (BBB) by transmembrane prolixity is cytokine- convinced neutrophil chemoattractant- 1(CINC- 1), which has a molecular weight of 7800 Dalton.

B. Saturable transport system: A saturable transport system is used by some specifics or composites with medicine- suchlike goods to cut the blood- brain barrier (BBB). Levo dopa (L- DOPA) and caffeine are two exemplifications. A transporter's endogenous ligand crosses the blood- brain barrier (BBB) at a rate that's around 10 times faster than would be anticipated if it did so via transmembrane prolixity. Also, several carriers for nonsupervisory motes, including peptides and proteins, are preferentially absorbed by particular brain areas. Saturable systems constantly regulate the rate at which their ligands cross the blood- brain barrier (BBB). For motes like glucose that depend on blood inflow, the transport rate is a function of that blood inflow. Several different agents can change how sluggishly moving particulars are carried. Leucine is an illustration of a peptide that controls the peptide transport system's rate of transport (PTS- 1). 3 The transport of motes across the brain walls shown in fig 4.



Fig. 4: Schematic representation of the transport of molecules across BBB.

Recent advances

1) Dendrimers
2) Scaffolds
3) Lipoplexes and Polyplexes
4) Modified nanoparticles
5) Receptor-mediated transport (RMT).
6) Transporter-independent mechanisms to circumvent the BBB.

I) Ultrasound (US)-mediated BBBD strategy

RECENT ADVANCES IN BRAIN TARGETING

1) Dendrimers: Dendrimers are fanned polymers, reminding the structure of a tree. A dendrimer is generally symmetric around the core, and when sufficiently extended it frequently adopts a spheroidal three- dimensional morphology in water. A central core can be honored in their structure with at least two identical chemical functionalities; starting from these groups, repeated units of other motes can appear, having at least one junction of branching. There desires of chains and raying result in a series of radially concentric layers with increased crowding. The structure is thus tightly packed in the fringe and approximately packed in the core, leaving spaces which play a crucial part in the medicine enmeshing capability of dendrimers. Poly(amidoamine), or PAMAM, is maybe the most well-known patch for conflation of dendrimers. The core of PAMAM is a diamine (generally ethylenediamine), which is replied with methyl acrylate and also with another ethylenediamine to make the generation 0PAMAM. consecutive responses produce advanced generations. Albertazzietal showed that functionalization of PAMAMs dendrimers has a dramatic effect on their capability to diffuse in the CNS towel in vivo and access living neurons as shown after intra parenchymal or intraventricular injections. Kannanetal. showed that systemically administered polyamidoamine dendrimers localize in actuated microglia and astrocytes in the brain of new born rabbits with cerebral paralysis, furnishing openings for clinical restatement in the treatment of neuro seditious diseases in humans.

2) Scaffolds: scaffolds are implantable and can be used to treat a variety of conditions associated with brain injury and conditions, for delivering medicines to treat neurological conditions similar as Parkinson's complaint and Alzheimer's complaint. Delivery of remedial agents from scaffolds potentially helps to limit the damage to neurons while helping to save their function. Although scaffolds have wide range of implicit operations for neural towel engineering, the brain presents analogous obstacles when designing scaffolds. Considerations include. Minimizing cell death and inflammation after implantation of scaffolds, by choosing biocompatible accoutrements Controlling medicine release over an applicable time period to help multiple surgeries or injections Making the whole process minimally invasive to save the integrity of the BBB Scaffolds should be small and minimally invasive.



Fig. 5: Scaffolds.

3) Lipoplexes and Polyplexes: In order to ameliorate the delivery of the new DNA into the cell, the DNA must be defended from damage and its entry into the cell must be eased. Lipoplexes and polyplexes serve this purpose. Both have the capability to cover the DNA from undesirable declination during the transfection process. Plasmid DNA can be covered with lipids in a systematized structure like a micelle or a liposome. When the systematized structure is perplexed with DNA it's called a lipoplex.

There are three types of lipids
1. Anionic (negatively charged)
2. Neutral
3. Cationic (positively charged)

Originally, anionic and neutral lipids were used for product of lipoplexes for synthetic vectors. Lipoplexes are compatible with body fluids, there's a possibility of conforming them to be towel specific and there's veritably little toxin associated with them. The only disadvantage is that they're complicated and time consuming to produce. therefore, attention was turned to the cationic performances. Cationic lipids, because of the positive charge on them, have capability to naturally complex with the negatively charged DNA. Also because of the positive charge, they interact with cell membrane, endocytosis of the lipoplex occurs and the DNA is released into the cytoplasm. The cationic lipids also cover against declination of the DNA by the cell. Cationic lipids include Dioleoyl phosphoethanolamine tip), dioleoyl trimethylammonium chloride (DOTMA). Complexes of polymers with DNA are called polyplexes. utmost polyplexes correspond of cationic polymers and they're formed by ionic relations. One large difference between the styles of action of lipoplexes and polyplexes is that polyplexes cannot release the associated DNA into the cytoplasm. For release to take place co-transfection with endosome- lytic agents which lyse the endosome must do and the polyplex enters the cell. Still this isn't always the case, polymers similar as Polyethyleneimine (PEI), chitosan and trimethyl chitosan have their own system of endosome dislocation. PEI forms thick nanosized particulates and complexes with negatively charged DNA by electrostatic relations. The PEI/ DNA complex takes overall positive charge and interacts with negatively charged factors of cell membranes and enter cells by endocytosis. The PEI/ DNA complex enters the cells by non-specific adsorption mediated endocytosis. Upon endocytosis, PEI undergoes farther protonation as the endosomal cube acidifies. Protonation of PEI occurs by landing protons, which is called as Proton Sponge medium. This leads to bibulous lump and posterior endosomal dislocation. Demonstrated that only one nuclear localization signal NLS) peptide covalently linked to DNA could increase the transfection efficacity following an intracellular injection of the plasmid.

4) Modified nanoparticles

The application of the nanoparticles as a vector for brain medicine delivery has the following advantages
- ✓ engineerability
- ✓ Non-toxicity.
- ✓ Controllable lading releasing of active agents (medicines discrepancy agents)
- ✓ Targeted nanoparticles can achieve the delivery of large quantities of remedial or imaging agents.
- ✓ The nanoparticles with enhanced face parcels (targeting and/ or hydrophilic coating) may be suitable to deliver a high quantum of medicines discrepancy agents widely to excrescence spots and ameliorate the efficacity of being imaging and treatment of cancer in general
- ✓ The exact medium of nanoparticle transport into the brain is most likely:
- ✓ Receptor- intermediated endocytosis
- ✓ Phagocytosis
- ✓ Passive leakage across blights in the BBB.

5) Receptor-mediated transport (RMT)

The BBB expresses RMT systems for the transport of endogenous peptides, similar as insulin or transferrin. The RMT systems operate in resemblant with the classical carrier- intermediated transporters (CMT), which transport certain small patch nutrients, vitamins, and hormones. Just as the CMT systems are doors of entry for small patch medicines that have a molecular structure that mimics that of an endogenous CMT substrate, the RMT systems are doors of entry for large patch medicines that are attached to endogenous RMT ligands.

6) Transporter-independent mechanisms to circumvent the BBB

CED is a system for original/ indigenous micro infusion targeted directly to brain towel. A nonstop infusion pressure grade over hours to days results in distribution of remedial agents into the interstitial space. The CED fashion is used primarily for large molecular weight agents that show minimum leakage across the BBB and/ or have significant systemic toxin, including contagions, oligonucleotides, nanoparticles, liposome, and targeted immunotoxins. Parameters that affect CED volume of distribution include infusion parameters rate, volume, duration, cannula size), infuscate characteristics (molecular weight, face parcels, towel affinity), and towel parcels (towel viscosity, extracellular space, vascularity, and interstitial fluid pressure). Beast studies have demonstrated that the volume of distribution achieved by CED can be imaged by glamorous resonance in real time by including discrepancy agents within the infuscate. The major clinical use of CED will be for targeted remedy of glioblastoma. Recent studies have included interleukin 13/ pseudomonas exotoxin alone or in combination with radiation/ temozolomide, and radioimmunotherapy with abs targeting tenascin or excrescence necrosis factor. Despite promising early results, it appears that two assiduity- patronized phase III trials of CED immunotoxins have been negative. Mechanisms for CED treatment failure include distribution inhomogeneity, high interstitial fluid pressure, and rapid-fire efflux of agent from the injection point. To overcome these issues, increased hearthstone time must be achieved to enhance targeted poison receptor list and uptake by the cancerous cells. Although primarily targeting brain excrescences, the CED fashion may also gain use for localized neurodegenerative diseases. For illustration, CED has been used to inoculate 6 glucocerebrosidase into the anterior lobe and brainstem of a case with neuronopathic Gaucher complaint. Infusion of adenovirus vectors or glial-deduced

neurotrophic factor has been assessed in Parkinson complaint.



Fig. 6: Illustration of convection-enhanced delivery.

I) Ultrasound (US)-mediated BBBD strategy

US consists of pressure waves having frequentness of 20 kHz or lesser. Like optic and audio waves, ultrasonic waves can be concentrated, reflected, and refracted through a medium. A major limitation in the application of US for BBBD has been the poor penetration of US through the cranium, and for several decades it was believed that the cranium bone had to be removed to perform US treatments in the brain. Still, experimental and theoretical studies have shown that it's doable to achieve focal, trans- cranium concentrated US(FUS) exposure of brain towel by using large face area phased arrays. Lately developed image- guided (eg, Magnetic resonance imaging (MRI)- guided) FUS clinical systems have made it possible to deliver rectifiers to the targeted regions in the brain through the complete cranium, and both beast studies and clinical trials have shown encouraging results. As shown in Figure, ultrasonic microbubbles combined with FUS can be used as medicine carriers for targeted microbubbles with narrow size distribution have been used to achieve an unremarkable cavitation terrain with controlled source of cavitation capitals. Cavitation is defined as the oscillation of bubbles in an aural field. Cavitation can produce strong stresses on cells to achieve colorful "bioeffects." For case, it may increase medicine commerce by upregulating pathways of colorful types of stress response, or affect in physical shearing of the cell membrane to promote direct passage of rectifiers into the cytosol. With ultrasonic microbubbles in blood vessels, the aural energy needed by the cavitation will be greatly reduced. This fashion makes the procedure more practical for operation through the complete cranium, since the pitfalls of overheating the cranium would be significantly reduced. likewise, with the use of these agents, the commerce of the US with the endothelial cells can be limited, so the chance of damage to other brain structures can be minimized.



Fig. 7: Illustration of ultrasonic microbubbles for drug targeted delivery.

CONCLUSION

Delivering Medicines effectively for treatment of CNS-related diseases is affected by lack of specific and efficient approaches. Despite these obstacles, significant progress has been made in the strategies for brain targeting. But none has been proved to be satisfactory. It can be concluded from this review that by means of the below mentioned approaches the medicine can be delivered across the BBB efficiently. Recent developments in medicine delivery across the BBB have proven to be helpful for prostrating walls associated with brain medicine delivery. therefore, these approaches can be useful in the brain targeting offers a bettered clinical effectiveness but still there's need of utmost dependable ways or styles which high clinical significance and cost effective.

ACKNOWLEGDGEMENT

The Author are thankful to principal, Dharashive V. M for providing encouragement and valuable guidance throughout the review work. Also I would like to thanks

my supervisor, for all his help guidance and assistance throughout the course of work.

REFERENCES

1. Swatantra Bahadur Singh. Novel Approaches for Brain Drug Delivery System-Review International Journal of Pharma Research & Review., June, 2013; 2(6): 36-44.
2. Ambikanandan Misra, Ganesh S., Aliasgar Shahiwala, Shrenik P. Shah. Drug delivery to the central nervous system: a review. Journal of Pharmacy & Pharmaceutical Sciences., 5 August, 2003; 6(2): 252-273.
3. Shobhit Kumar, Satish Kumar Gupta, Pramod Kumar Sharma. Recent Developments In Targeted Drug Delivery System For Crossing Blood brain Barrier: A Review. International Journal of Pharmacy and Pharmaceutical Sciences., 28 Dec, 2011; 4(2): 2012.
4. Jinal Prajapati, Hardik Patel, Yadvendra. K. Agrawal. Targeted Drug Delivery for Central Nervous System: A Review. International Journal of Pharmacy and Pharmaceutical Sciences., 19 Apr, 2012; 4(3): 2012.
5. Shadab A. Pathan, Zeenat Iqbal, Syed M. A. Zaidi, Sushma Talegaonkar, Divya Vohra, Gaurav K. Jain, et al. CNS Drug Delivery Systems: Novel Approaches. Recent Patents on Drug Delivery & Formulation., 28 Nov., 2008; 3: 71-8.
6. Bummer PM, Physical chemical considerations of lipid based oral drug delivery, solid lipid nanoparticles, Critical Review, Therpeutic Drug Carrier System, 2004; 21(2): 1-20.
7. Shrikant CS, Mahale NB, Chaudhari SR, Thorat RS, Recent advances in brain targeted drug delivery system: a review, 2015; 4(5): 542-559.
8. Ganesh S, Shahiwal A, Shrenik P, Drug delivery to the central nervous system: a review, Received 16 June 2003, Revised 26 June 2003.
9. Bickel U, how to measure drug transport across the blood brain barrier, Neuro Rx, 2005; 2: 15–26.
10. Tamai I, Tsuji A, Transporter-mediated permeation of drugs across the blood–brain barrier. J Pharm Sci., 2000; 89: 1371–1388.
11. Pardridge WM, Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS., 2011; 8: 7.
12. Rip J, Schenk GJ, de Boer AG, Differential receptor-mediated drug targeting to the diseased brain. Expert Opin. Drug Deliv, 2009; 6(3): 227–237.
13. Bickel U, Yoshikawa T, Pardridge WM, Delivery of peptides and proteins through the blood–brain barrie, Adv. Drug Deliv. Rev., 2001; 46(1–3): 247–279.
14. Lu W, Wan J, She Z, Jiang X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated PEGylated nanoparticle. J. Control. Release, 2007; 118(1): 38–53.
15. Kabanov AV, Batrakova EV, New technologies for drug delivery across the blood brain barrier, Curr Pharm Des, 2004; 10: 1355-1363.
16. Varsha Z, Gite VZ, Ghume VK, Kachave RN, "Brain Targeted Drug Delivery System" World Journal of Pharmaceutical and Medical Research, 2020; 6(11): 45-57.
17. 9. Singh SB, "Novel approaches for brain drug delivery system-review" International Journal of Pharma Research & Review, 2013; 2(6): 36-44.
18. Amrita Dikpati, AR Madgulkar, Sanjay J Kshirsagar, MR Bhalekar, Andeep Singh Chahal, Amrita Dikpati. Targeted Drug Delivery to CNS using Nanoparticles. Journal of Advanced Pharmaceutical Sciences., 2012; 3: 2(1).
19. Aasavari H. Gupte, Harsha T. Kathpalia. Recent Advances in Brain Targeted Drug Delivery Systems: A Review. International Journal of Pharmacy and Pharmaceutical Sciences, 16 Dec, 2013; 6(2): 2014.
20. Massimo Masserini. Nanoparticles for Brain Drug Delivery. Hindawi Publishing Corporation. Biochemistry., April, 2013.
21. Nuno Martinho, Christiane Damgé, Catarina Pinto Reis. Recent Advances in Drug Delivery Systems Journal of Biomaterials and Nanobiotechnology, 2011; 2: 510-526.
22. Shivaraju*, Gk Avinash, S Parthiban, Sk Senthilkumar. Nanoparticles as Specified Carriers In Targeted Brain Drug Delivery System. International Journal of Pharmaceutical Development & Technology., 2013; 3(1): 1-6.
23. Maiken Nedergaard, William Pardridge, Eain Cornford. Delivery and The Brain Barriers. International Brain Barriers Society., 01-33.
24. Reinhard Gabathuler. Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases. Neurobiology of Disease., 5 August 2009.
25. Cui-Tao Lu, Ying-Zheng Zhao, Ho Lun Wong, Jun Cai, Lei Peng, Xin-Qiao Tian. Current approaches to enhance CNS delivery of drugs across the brain barriers. International Journal of Nanomedicine., May 2014; 9: 2241–2257.